NASDAQ:PRAHPRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRAH stock has increased by 14.3% and is now trading at $101.38.
View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PRA Health Sciences.

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PRA Health Sciences.

PRA Health Sciences Inc (NASDAQ:PRAH) announced its earnings results on Thursday, August, 6th. The medical research company reported $0.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $0.22. The medical research company earned $729.89 million during the quarter, compared to analysts' expectations of $716.12 million. PRA Health Sciences had a net margin of 6.86% and a return on equity of 25.01%. The firm's revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.22 earnings per share.
View PRA Health Sciences' earnings history.

PRA Health Sciences issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of $4.35 to $4.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $3.07 billion to $3.13 billion, compared to the consensus revenue estimate of $3.07 billion.

13 brokers have issued 1-year price targets for PRA Health Sciences' shares. Their forecasts range from $89.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $105.75 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts' price targets for PRA Health Sciences.

Headlines about PRAH stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about PRA Health Sciences.

PRA Health Sciences saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 1,160,000 shares, a drop of 18.3% from the July 15th total of 1,420,000 shares. Based on an average daily trading volume, of 396,500 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.8% of the shares of the company are short sold.
View PRA Health Sciences' Short Interest.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Applied Materials (AMAT), Adobe (ADBE), Abbott Laboratories (ABT), Walt Disney (DIS), Paypal (PYPL), Veeva Systems (VEEV), AbbVie (ABBV) and Broadcom (AVGO).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include NN Investment Partners Holdings N.V. (2.32%), NN Investment Partners Holdings N.V. (2.30%), Pendal Group Ltd (1.61%), TimesSquare Capital Management LLC (0.90%), Principal Financial Group Inc. (0.31%) and Fisher Asset Management LLC (0.29%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Smith Asset Management Group LP, UBS Group AG, FDx Advisors Inc., Russell Investments Group Ltd., Pendal Group Ltd, Tygh Capital Management Inc., and Avalon Investment & Advisory. Company insiders that have sold PRA Health Sciences company stock in the last year include Fund Holdings LP Kkr, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Bank of Nova Scotia, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Mackay Shields LLC, Healthcare of Ontario Pension Plan Trust Fund, Fisher Asset Management LLC, and Swiss National Bank.
View insider buying and selling activity for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $101.38.

PRA Health Sciences has a market capitalization of $6.46 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

The official website for PRA Health Sciences is www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]